TY - JOUR
T1 - Association of APOE Genotypes and Chronic Traumatic Encephalopathy
AU - Atherton, Kathryn
AU - Han, Xudong
AU - Chung, Jaeyoon
AU - Cherry, Jonathan D.
AU - Baucom, Zachary
AU - Saltiel, Nicole
AU - Nair, Evan
AU - Abdolmohammadi, Bobak
AU - Uretsky, Madeline
AU - Khan, Mohammed Muzamil
AU - Shea, Conor
AU - Durape, Shruti
AU - Martin, Brett M.
AU - Palmisano, Joseph N.
AU - Farrell, Kurt
AU - Nowinski, Christopher J.
AU - Alvarez, Victor E.
AU - Dwyer, Brigid
AU - Daneshvar, Daniel H.
AU - Katz, Douglas I.
AU - Goldstein, Lee E.
AU - Cantu, Robert C.
AU - Kowall, Neil W.
AU - Alosco, Michael L.
AU - Huber, Bertrand R.
AU - Tripodis, Yorghos
AU - Crary, John F.
AU - Farrer, Lindsay
AU - Stern, Robert A.
AU - Stein, Thor D.
AU - McKee, Ann C.
AU - Mez, Jesse
N1 - Funding Information:
Funding/Support: This work was supported by the National Institute of Neurological Disorders and Stroke (grants U01NS086659, U01NS093334, U54NS115266, R01NS078337, R56NS078337, K23NS102399), National Institute of Aging (grants P30AG13846; supplement 0572063345, R01AG057902, R01AG061028, K23AG046377, R01AG1649, R01AG062348, R21HD089088, F32NS096803, F32AG056098), National Center for Advancing Translational Sciences (grant 1UL1TR001430), Department of Veterans Affairs (grants I01 CX001135, CSP 501, B6796-C, I01-CX001038), Department of Defense (grants W81XWH-13-2-0095, W81XWH-13-2-0064, W81XWH1810580, PRARP-13267017), the Alzheimer’s Association (grants NIRG-15-362697, NIRG-305779), the National Operating Committee on Standards for Athletic Equipment, the Nick and Lynn Buoniconti Foundation, the Concussion Legacy Foundation, the Andlinger Foundation, the WWE, and the NFL.
Funding Information:
reported nonfinancial support from Concussion Legacy Foundation during the conduct of the study. Dr Farrell reported grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Nowinski is the cofounder and chief executive officer of the Concussion Legacy Foundation; reported nonfinancial support (travel reimbursement) from the NFL Players Association as a member of the Mackey-White Health & Safety Committee, WWE, and AEW (All Elite Wrestling); personal fees (stock options) from Oxeia Biopharmaceuticals, PreCon Health, and Aurora CTS; and serves as an advisor for Oxeia Biopharmaceuticals and PreCon Health outside the submitted work. Dr Katz reported grants from National Institute of Neurological Disorders and Stroke and Boston University School of Medicine Department of Neurology during the conduct of the study; royalties from Springer/Demos Publishing for a textbook on brain injury; serves as an expert witness in legal cases involving brain injury and concussion; receives a stipend from Encompass Health as program medical director for brain injury and chair of the annual Neurorehabilitation conference; and has received honoraria for a keynote address for the HealthSouth Annual Medical Directors Meeting. Dr Goldstein is a paid consultant to Johnson & Johnson, Janssen Research & Development LLC, and Rebiscan Inc and has received funding from the WWE and Ivivi Health Sciences. Dr Cantu reported royalties from Houghton Mifflin Harcourt; compensation for expert legal opinion to the National Collegiate Athletic Association and National Hockey League; consults for the Concussion Legacy Foundation; is senior advisor and paid consultant to the NFL Head Neck & Spine Committee; is a member of the Mackey-White Committee of the National Football League Players Association; is vice president of National Operating Committee on Standards for Athletic Equipment and chair scientific advisory committee and cofounder of Medical Director Concussion Legacy Foundation; and is on the Medical Science Committee for the National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation. Dr Alosco reported grants from NIH during the conduct of the study and receives royalties from Oxford University Press for a textbook outside the submitted work. Dr Stern reported grants from NIH during the conduct of the study; personal fees from Biogen and Lundbeck outside the submitted work; member of the Mackey-White Committee of the National Football League Players Association; receives royalties for published neuropsychological tests from Psychological Assessment Resources Inc; and is a member of the Board of Directors of King-Devick Technologies. Dr McKee is a member of the Mackey-White Committee of the National Football League Players Association and reports other funding from Buoniconti Foundation during the conduct of the study. No other disclosures were reported.
Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022/8
Y1 - 2022/8
N2 - Importance: Repetitive head impact (RHI) exposure is the chief risk factor for chronic traumatic encephalopathy (CTE). However, the occurrence and severity of CTE varies widely among those with similar RHI exposure. Limited evidence suggests that the APOEϵ4 allele may confer risk for CTE, but previous studies were small with limited scope. Objective: To test the association between APOE genotype and CTE neuropathology and related endophenotypes. Design, Setting, and Participants: This cross-sectional genetic association study analyzed brain donors from February 2008 to August 2019 from the Veterans Affairs-Boston University-Concussion Legacy Foundation Brain Bank. All donors had exposure to RHI from contact sports or military service. All eligible donors were included. Analysis took place between June 2020 and April 2022. Exposures: One or more APOEϵ4 or APOEϵ2 alleles. Main Outcomes and Measures: CTE neuropathological status, CTE stage (0-IV), semiquantitative phosphorylated tau (p-tau) burden in 11 brain regions (0-3), quantitative p-tau burden in the dorsolateral frontal lobe (log-transformed AT8+ pixel count per mm2), and dementia. Results: Of 364 consecutive brain donors (100% male; 53 [14.6%] self-identified as Black and 311 [85.4%] as White; median [IQR] age, 65 [47-77] years) 20 years or older, there were 294 individuals with CTE and 70 controls. Among donors older than 65 years, APOEϵ4 status was significantly associated with CTE stage (odds ratio [OR], 2.34 [95% CI, 1.30-4.20]; false discovery rate [FDR]-corrected P =.01) and quantitative p-tau burden in the dorsolateral frontal lobe (β, 1.39 [95% CI, 0.83-1.94]; FDR-corrected P = 2.37 × 10-5). There was a nonsignificant association between APOEϵ4 status and dementia (OR, 2.64 [95% CI, 1.06-6.61]; FDR-corrected P =.08). Across 11 brain regions, significant associations were observed for semiquantitative p-tau burden in the frontal and parietal cortices, amygdala, and entorhinal cortex (OR range, 2.45-3.26). Among football players, the APOEϵ4 association size for CTE stage was similar to playing more than 7 years of football. Associations were significantly larger in the older half of the sample. There was no significant association for CTE status. Association sizes were similar when donors with an Alzheimer disease neuropathological diagnosis were excluded and were reduced but remained significant after adjusting for neuritic and diffuse amyloid plaques. No associations were observed for APOEϵ2 status. Models were adjusted for age at death and race. Conclusions and Relevance: APOEϵ4 may confer increased risk for CTE-related neuropathological and clinical outcomes among older individuals with RHI exposure. Further work is required to validate these findings in an independent sample.
AB - Importance: Repetitive head impact (RHI) exposure is the chief risk factor for chronic traumatic encephalopathy (CTE). However, the occurrence and severity of CTE varies widely among those with similar RHI exposure. Limited evidence suggests that the APOEϵ4 allele may confer risk for CTE, but previous studies were small with limited scope. Objective: To test the association between APOE genotype and CTE neuropathology and related endophenotypes. Design, Setting, and Participants: This cross-sectional genetic association study analyzed brain donors from February 2008 to August 2019 from the Veterans Affairs-Boston University-Concussion Legacy Foundation Brain Bank. All donors had exposure to RHI from contact sports or military service. All eligible donors were included. Analysis took place between June 2020 and April 2022. Exposures: One or more APOEϵ4 or APOEϵ2 alleles. Main Outcomes and Measures: CTE neuropathological status, CTE stage (0-IV), semiquantitative phosphorylated tau (p-tau) burden in 11 brain regions (0-3), quantitative p-tau burden in the dorsolateral frontal lobe (log-transformed AT8+ pixel count per mm2), and dementia. Results: Of 364 consecutive brain donors (100% male; 53 [14.6%] self-identified as Black and 311 [85.4%] as White; median [IQR] age, 65 [47-77] years) 20 years or older, there were 294 individuals with CTE and 70 controls. Among donors older than 65 years, APOEϵ4 status was significantly associated with CTE stage (odds ratio [OR], 2.34 [95% CI, 1.30-4.20]; false discovery rate [FDR]-corrected P =.01) and quantitative p-tau burden in the dorsolateral frontal lobe (β, 1.39 [95% CI, 0.83-1.94]; FDR-corrected P = 2.37 × 10-5). There was a nonsignificant association between APOEϵ4 status and dementia (OR, 2.64 [95% CI, 1.06-6.61]; FDR-corrected P =.08). Across 11 brain regions, significant associations were observed for semiquantitative p-tau burden in the frontal and parietal cortices, amygdala, and entorhinal cortex (OR range, 2.45-3.26). Among football players, the APOEϵ4 association size for CTE stage was similar to playing more than 7 years of football. Associations were significantly larger in the older half of the sample. There was no significant association for CTE status. Association sizes were similar when donors with an Alzheimer disease neuropathological diagnosis were excluded and were reduced but remained significant after adjusting for neuritic and diffuse amyloid plaques. No associations were observed for APOEϵ2 status. Models were adjusted for age at death and race. Conclusions and Relevance: APOEϵ4 may confer increased risk for CTE-related neuropathological and clinical outcomes among older individuals with RHI exposure. Further work is required to validate these findings in an independent sample.
UR - http://www.scopus.com/inward/record.url?scp=85133408356&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2022.1634
DO - 10.1001/jamaneurol.2022.1634
M3 - Article
C2 - 35759276
AN - SCOPUS:85133408356
SN - 2168-6149
VL - 79
SP - 787
EP - 796
JO - JAMA Neurology
JF - JAMA Neurology
IS - 8
ER -